Zilbrysq 32.4 mg solution for injection in pre-filled syringe
Sponsors
UCB Biopharma
Conditions
Generalized Myasthenia Gravis
Phase 2
Phase 3
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ACTIVITY OF ZILUCOPLAN IN PEDIATRIC STUDY PARTICIPANTS WITH ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE GENERALIZED MYASTHENIA GRAVIS
RecruitingCTIS2022-502073-42-00
Start: 2025-08-18Target: 4Updated: 2025-12-17
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Active, not recruitingCTIS2024-512399-37-00
Start: 2020-12-29Target: 37Updated: 2025-12-03